Assessment of endpoint definitions in curative-intent trials for mucosal head and neck squamous cell carcinomas: head and neck cancer international group consensus recommendations
Authors
Lim, A. M.McDowell, L.
Hurt, C.
Le Tourneau, C.
Homma, A.
Shenouda, G.
Thomson, David J
Moya-Plana, A.
Henson, C.
Szturz, P.
Day, A. T.
Bates, J. E.
Lazarakis, S.
Thariat, J.
Psyrri, A.
Mehanna, H.
Yom, S. S.
Affiliation
The Christie NHS Foundation Trust, Manchester Academic Health Sciences Centre, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.Issue Date
2024
Metadata
Show full item recordAbstract
Robust time-to-event endpoint definitions are crucial for the assessment of treatment effect and the clinical value of trial interventions. Here, the Head and Neck Cancer International Group investigated endpoint use in phase 3 trials and trials considered potentially practice-changing published between 2008 and 2021 in the curative-intent setting for patients with mucosal head and neck squamous cell carcinoma. Of the 92 trials reviewed, we show that all core components of endpoint reporting were heterogeneous, including definitions of common terms, such as overall survival and progression-free survival. Our report highlights the urgent need for harmonisation of fundamental components of clinical trial endpoints and the engagement of all stakeholders to ensure the transparent reporting of endpoint details.Citation
Lim AM, McDowell L, Hurt C, Le Tourneau C, Homma A, Shenouda G, et al. Assessment of endpoint definitions in curative-intent trials for mucosal head and neck squamous cell carcinomas: Head and Neck Cancer International Group consensus recommendations. The Lancet Oncology. 2024 Jul;25(7):e318-e30.Journal
Lancet OncologyDOI
10.1016/s1470-2045(24)00067-6PubMed ID
38936390Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/s1470-2045(24)00067-6
Scopus Count
Collections
Related articles
- Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations.
- Authors: Lim AM, Le Tourneau C, Hurt C, Laskar SG, Steuer CE, Chow VLY, Szturz P, Henson C, Day AT, Bates JE, Lazarakis S, McDowell L, Mehanna H, Yom SS, HNCIG
- Issue date: 2024 Jul
- Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions.
- Authors: Haddad RI, Posner M, Hitt R, Cohen EEW, Schulten J, Lefebvre JL, Vermorken JB
- Issue date: 2018 May 1
- Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial.
- Authors: Hitt R, Iglesias L, López-Pousa A, Berrocal-Jaime A, Grau JJ, García-Girón C, Martínez-Trufero J, Guix M, Lambea-Sorrosal J, Del Barco-Morillo E, León-Vintró X, Cunquero-Tomas AJ, Baste N, Ocaña A, Cruz-Hernández JJ, the Spanish Head and Neck Cancer Cooperative Group (TTCC)
- Issue date: 2021 Apr
- A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma.
- Authors: Keam B, Lee KW, Lee SH, Kim JS, Kim JH, Wu HG, Eom KY, Kim S, Ahn SH, Chung EJ, Kwon SK, Jeong WJ, Jung YH, Kim JW, Heo DS
- Issue date: 2019 Jun
- Treatment Package Time in Node-Positive Cutaneous Head and Neck Squamous Cell Carcinoma.
- Authors: Daniels CP, Bressel M, Corry J, Cole A, Chua MS, Tiong A, Hirshoren N, Dixon B, McDowell L
- Issue date: 2020 Jan-Feb